[Therapeutic efficacy of Nexavar on liver cancer and its relation to the expression of Ki-67 and CD34].
OBJECTIVE
To study the therapeutic effects of Nexavar on liver cancer and its relation to the expressions of Ki-67 and CD34.


METHODS
Twenty-eight patients with liver cancer were treated with Nexavar. The therapeutic efficacy of Nexavar on liver cancer was observed. Liver cancer tissues were examined for the expressions of Ki-67 and CD34 by immunohistochemistry. Microvessel density (MVD) was calculated according to the expression of CD34.


RESULTS
Of 28 patients, none achieved a complete response (CR), 12 had a partial response (PR), 7 had stable disease (SD), and 9 progressive disease (PD). The efficacy of Nexavar was associated significantly with Ki-67 expression. The mean MVD count was 346.03-/+146.98 in PR patients, and 89.14-/+45.66 in PD patients. There was a significant difference in MVD between PR and PD patients.


CONCLUSIONS
There is a better efficacy of Nexavar in treatment of liver cancer in the patients who had Ki-67-positive expression and high MVD count.
Kan
He-ping
HP
Department of Hepatobilliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. kanhep@fimmu.com
Wang
Yu
Y
Tan
Yong-fa
YF
Zhou
Jie
J
D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D000077157:Sorafenib
D018952:Antigens, CD34; D000970:Antineoplastic Agents; D019394:Ki-67 Antigen; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib